Jamie Gould, Consultant at The RSA Group, explores the talent landscape of the immuno-oncology sector. Immuno-oncology harnesses the power of the body’s immune system to fight cancer. This exciting field is rapidly evolving and already delivering a revolution in cancer therapeutics with a steady stream of recent approvals. In June 2024, the FDA approved Merck’s […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!